99 related articles for article (PubMed ID: 28067383)
1. The functional consequences and prognostic value of dosage sensitivity in ovarian cancer.
Yan Z; Liu Y; Wei Y; Zhao N; Zhang Q; Wu C; Chang Z; Xu Y
Mol Biosyst; 2017 Jan; 13(2):380-391. PubMed ID: 28067383
[TBL] [Abstract][Full Text] [Related]
2. An integrated approach to reveal miRNAs' impacts on the functional consequence of copy number alterations in cancer.
Li K; Liu Y; Zhou Y; Zhang R; Zhao N; Yan Z; Zhang Q; Zhang S; Qiu F; Xu Y
Sci Rep; 2015 Jun; 5():11567. PubMed ID: 26099552
[TBL] [Abstract][Full Text] [Related]
3. ICan: an integrated co-alteration network to identify ovarian cancer-related genes.
Zhou Y; Liu Y; Li K; Zhang R; Qiu F; Zhao N; Xu Y
PLoS One; 2015; 10(3):e0116095. PubMed ID: 25803614
[TBL] [Abstract][Full Text] [Related]
4. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
Xu Z; Zhou Y; Cao Y; Dinh TL; Wan J; Zhao M
Med Oncol; 2016 Nov; 33(11):130. PubMed ID: 27757782
[TBL] [Abstract][Full Text] [Related]
5. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.
Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723
[TBL] [Abstract][Full Text] [Related]
6. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
[TBL] [Abstract][Full Text] [Related]
7. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
8. Synergetic regulatory networks mediated by oncogene-driven microRNAs and transcription factors in serous ovarian cancer.
Zhao M; Sun J; Zhao Z
Mol Biosyst; 2013 Dec; 9(12):3187-98. PubMed ID: 24129674
[TBL] [Abstract][Full Text] [Related]
9. Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis.
Zhang ST; Zuo C; Li WN; Fu XQ; Xing S; Zhang XP
Arch Gynecol Obstet; 2016 Feb; 293(2):421-7. PubMed ID: 26264810
[TBL] [Abstract][Full Text] [Related]
10. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
11. A novel framework for inferring condition-specific TF and miRNA co-regulation of protein-protein interactions.
Zhang J; Le TD; Liu L; He J; Li J
Gene; 2016 Feb; 577(1):55-64. PubMed ID: 26611531
[TBL] [Abstract][Full Text] [Related]
12. Integrative network analysis of TCGA data for ovarian cancer.
Zhang Q; Burdette JE; Wang JP
BMC Syst Biol; 2014 Dec; 8():1338. PubMed ID: 25551281
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Hypoxiamir-Gene Regulatory Network Identifies Critical MiRNAs Influencing Cell-Cycle Regulation Under Hypoxic Conditions.
Gupta A; Ragumani S; Sharma YK; Ahmad Y; Khurana P
Microrna; 2019; 8(3):223-236. PubMed ID: 30806334
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression.
Guo Q; Cheng Y; Liang T; He Y; Ren C; Sun L; Zhang G
Sci Rep; 2015 Dec; 5():17683. PubMed ID: 26631459
[TBL] [Abstract][Full Text] [Related]
15. Concordant dysregulation of miR-5p and miR-3p arms of the same precursor microRNA may be a mechanism in inducing cell proliferation and tumorigenesis: a lung cancer study.
Mitra R; Lin CC; Eischen CM; Bandyopadhyay S; Zhao Z
RNA; 2015 Jun; 21(6):1055-65. PubMed ID: 25852169
[TBL] [Abstract][Full Text] [Related]
16. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
17. Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line.
Jayavelu ND; Bar N
BMC Genomics; 2015 Dec; 16():1077. PubMed ID: 26763900
[TBL] [Abstract][Full Text] [Related]
18. Characterization of microRNA expression in serous ovarian carcinoma.
Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
[TBL] [Abstract][Full Text] [Related]
19. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
20. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
